Moderna Publishes Presentation on Phase 3 Intismeran Melanoma Study

Bitget2026/10/24 17:05

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Moderna published an oncology presentation featuring Phase 3 INTerpath-001 results for individualized cancer therapy intismeran autogene.
The trial compares intismeran autogene with pembrolizumab against pembrolizumab alone as adjuvant treatment for resected stage IIB-IV melanoma.
The presentation reports a recurrence-free survival benefit maintained through five years of follow-up.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Moderna Inc. published the original content used to generate this news brief on October 24, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Moderna Publishes Presentation on Phase 3 Intismeran Melanoma Study

You may also like

Crypto prices